



# Selection of rabbit B-cell generated recombinant antibodies using a highly sensitive SPR instrument

**Intellectual Property Notice:** Part of GE Healthcare's Life Sciences business was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

## cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.  
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.  
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.  
All other third-party trademarks are the property of their respective owners.  
© 2020 Cytiva  
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.  
For local office contact information, visit [cytiva.com/contact](https://cytiva.com/contact)

CY16468-10Sep20-PT




# Selection of rabbit B-cell generated recombinant antibodies using a highly sensitive SPR instrument

Brian Lang<sup>1</sup>, Michael Schräml<sup>2</sup>, Leopold von Proff<sup>2</sup>, Pelle Lidström<sup>1</sup> and Olof Karlsson<sup>1</sup>

<sup>1</sup> GE Healthcare, Uppsala, Sweden <sup>2</sup> Roche Professional Diagnostics, Penzberg, Germany

Antibodies produced using Rabbit B-cells are often obtained in low concentrations. When performing kinetic screening of these antibodies towards small peptides or small molecules, the sensitivity of the analysis systems becomes very important. Another major hurdle has been how to efficiently evaluate the data and select the best candidates for further evaluation. In this study, the highly sensitive Biacore™ T200 equipped with a new software was used to efficiently select the top candidates for further characterization.

## What does Biacore™ measure



The sensorgram provides real time information about the entire interaction. Kinetics can be calculated from the curvature during injection (orange) and dissociation (blue). Antibodies are normally characterized by very strong binding with very slow dissociation.


## Selection process



- Rabbits were immunized with a 13 kDa chemokine
- 64 Rab-mAb:s were selected and produced for kinetic screening
- Kinetic screening using three different recombinant chemokine derivatives was performed
- Rab-mAb:s with desired binding kinetics to all three chemokines were selected

## Kinetic screening assay set-up

The kinetic screen was performed using an efficient capture approach optimizing the throughput of the system. By this approach up to 130 Rab-mAbs can be screened and evaluated in 24h.



### Capture


Chip CM5\*  
Goat anti-rabbit Fc γ

### Ab

Rec rabbit mAbs

### Ag

3 different recombinant derivatives  
Ag1: wild type  
Ag2: mutant  
Ag3: wild type, tag-free




- A reference Ab was captured in flow cell 1
- Three Rabbit-mAbs were captured in every cycle, one in each of three flowcells
- All four flow cells were addressed with antigen
- The whole surface was regenerated and ready for another cycle


## Kinetic Screening data evaluation

### Assess data quality - Overview the series

Enhanced evaluation software allow several runs to be co-evaluated if required. Up to 200 concentration series can be simultaneously evaluated. Rapid qualification and pre-fit selection of only relevant data in the thumbnail view sped up the evaluation by minimizing the fitting time. In addition, automated QC tools provided fast fit-quality assessments, enabling confident interpretation of results.




Pre-fit overview allows rapid pre-qualification of the data set.



Post-fit overview with automated fit assessment allows for confident result interpretation.


### Result summary and antibody selection




The results are visualized in an on-off rate map and displayed in a customizable result table. Using these tools the top ten antibodies towards each antigen could be quickly identified.

The on-off rate map gives a full overview of the kinetic parameters and affinities of the analyzed antibodies.

Five antibodies were identified that exhibited promising binding kinetic properties towards all three antigens.



Rab-mAb No.	$k_a \times 10^5$	$k_d \times 10^5$	$K_D \times 10^{-11}$
48	7.3 – 14	6.1 – 20	8.4 – 14
47	8.6 – 17	13 – 23	11 – 25
40	11 – 25	24 – 26	10 – 21
39	10 – 22	29 – 34	14 – 32
35	11 – 23	31 – 35	15 – 28



Using Biacore T200 it was possible to retrieve kinetic information from this 1.2kDa glycosylated peptide with only 400RU of rabbit-mAb captured on the surface. The analysis was performed at 37°C.

The high sensitivity of the system allows kinetic information to be retrieved from antibodies expressed in low concentrations minimizing the number of false negatives.

## Conclusions

Kinetic screening using Biacore™ T200 has proven very valuable in the selection of rabbit B-cell generated antibodies for diagnostic purposes. The high sensitivity and the new evaluation tools have improved the ability to select promising antibodies based on their kinetic characteristics also for antibodies expressed at low levels and antibodies interacting with small molecules.

- Five Rab-mAb:s were rapidly identified for further characterization (e.g. binding thermodynamics)
- Valuable kinetic data was obtained also at very low expression levels
- The new Biacore T200 software fully supported the kinetic screen evaluation by means of overview, functionality and flexibility



imagination at work

GE, imagination at work, and GE monogram are trademarks of General Electric Company. Biacore and MicroCal are trademarks of GE Healthcare companies. All third party trademarks are the property of their respective owners. © 2013 General Electric Company - All rights reserved. First published April 2013

All goods and services are sold subjects to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information. GE Healthcare Bio-sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden 29-0517-23 AA